


Silva Pharmaceuticals Limited

Un-Audited Financial Statements (First Quarter)

For the Period from 01 July, 2021 to 30 September, 2021

Silva Pharmaceuticals Limited
Statement of Financial Position (Un-Audited)
As at 30 September, 2021

Particulars	Notes	Amount in Taka	
		30-Sep-21	30-Jun-21
ASSETS			
Non Current Assets		1,421,878,466	1,372,217,229
Property, Plant and Equipment	3.00	1,209,902,574	1,175,793,246
Intangible Assets	4.00	1,637,891	1,679,888
Right-of-use asset (ROU)	5.00	14,793,534	16,275,117
Capital work-in-Progress	6.00	195,544,467	178,468,978
Current Assets		1,079,430,675	1,074,937,836
Inventories	7.00	464,492,032	464,181,830
Trade and Other Receivables	8.00	273,922,317	272,213,765
Advances, Deposits and Prepayments	9.00	77,275,619	68,212,863
Fixed Deposits Receipts (FDR)		224,064,638	211,666,669
Cash and Cash Equivalents	10.00	39,676,069	58,662,709
Total Assets		2,501,309,141	2,447,155,065
SHAREHOLDERS EQUITY AND LIABILITIES:			
Equity attributable to the Shareholders		2,309,582,526	2,270,472,128
Share Capital	11.00	1,365,000,000	1,365,000,000
Retained Earnings	12.00	944,582,526	905,472,128
Non-Current Liabilities		89,535,228	88,198,786
Deferred Tax Liabilities	13.00	81,735,188	80,303,550
Lease Liabilities	14.00	7,800,040	7,895,236
Current Liabilities		102,191,387	88,484,151
Lease Liabilities	14.00	4,286,894	5,673,281
Trade and Other Payables	15.00	6,703,859	6,253,488
Unclaimed Dividend Account		1,487,936	1,519,762
Short Term Loan		28,777,212	29,136,806
Provision for Expenses	16.00	60,935,486	45,900,814
Total Liabilities		191,726,615	176,682,937
Total Equity & Liabilities:		2,501,309,141	2,447,155,065
Net Assets Value (NAV) per share	23.00	16.92	16.63
Number of Shares used to compute NAV		136,500,000	136,500,000



Chairman



Managing Director



Director



Chief Financial Officer



Company Secretary

Silva Pharmaceuticals Limited

Statements of Profit or Loss and other Comprehensive Income (Un-Audited)

For the First Quarter ended 30 September, 2021

Particulars	Notes	Amount in Taka	
		July - September, 2021	July - September, 2020
Revenue		215,851,753	227,521,337
Cost of goods sold	17.00	(120,985,622)	(127,252,357)
Gross Profit		94,866,131	100,268,980
Operating expenses		(43,277,507)	(37,302,643)
Administrative Expenses	18.00	(10,300,651)	(8,953,552)
Selling & Distribution Expenses	19.00	(32,976,856)	(28,349,091)
Operating Income		51,588,624	62,966,337
Financial expenses		(556,081)	(682,039)
Other income		2,537,743	3,797,573
Net Operating Profit		53,570,286	66,081,871
Workers' Profit Participation and Welfare Fund (WPP&WF)	20.00	(2,550,966)	(3,146,756)
Net Profit before Income Tax		51,019,320	62,935,115
Income Tax Expenses:		(11,908,922)	(15,763,404)
Current Tax Expenses	21.01	(10,477,284)	(14,813,522)
Deferred Tax Income /(Expenses)	21.02	(1,431,638)	(949,882)
Net Profit after tax		39,110,398	47,171,711
Other Comprehensive Income		-	-
Total comprehensive income for the year		39,110,398	47,171,711
Earnings per Share (EPS)	22.00	0.29	0.35
Number of Shares used to compute EPS		136,500,000	136,500,000



Chairman



Managing Director



Director



Chief Financial Officer



Company Secretary

Silva Pharmaceuticals Limited
Statement of Changes in Equity (Un-Audited)
For the First Quarter ended 30 September, 2021

Particulars	<i>(Amount in Taka)</i>		
	Share Capital	Retained Earnings	Total
Balance as on 1st July, 2021	1,365,000,000	905,472,128	2,270,472,128
Net profit after tax during the period	-	39,110,398	39,110,398
Balance as at 30 September, 2021	1,365,000,000	944,582,526	2,309,582,526

Silva Pharmaceuticals Limited
Statement of Changes in Equity
For the First Quarter ended 30 September, 2020


Particulars	<i>(Amount in Taka)</i>		
	Share Capital	Retained Earnings	Total
Balance as on 1st July, 2020	1,365,000,000	833,109,877	2,198,109,877
Net profit after tax during the period	-	47,171,711	47,171,711
Balance as at 30 September, 2020	1,365,000,000	880,281,588	2,245,281,588



Chairman



Managing Director



Director



Chief Financial Officer



Company Secretary

Silva Pharmaceuticals Limited

Statement of Cash Flows (Un-Audited)

For the First Quarter ended 30 September, 2021

Particulars	Notes	Amount in Taka	
		July - September, 2021	July - September, 2020
Cash flows from Operating Activities			
Cash received from Customers	24.00	215,804,786	225,917,479
Cash received from non-operating income	25.00	876,158	773,570
Cash Paid to Suppliers	26.00	(101,948,471)	(117,915,717)
Cash Paid to Employees	27.00	(37,514,733)	(31,535,804)
Cash Paid for Others	28.00	(6,117,112)	(6,969,660)
Income Tax Paid	29.00	(9,093,267)	(12,732,908)
Net cash flows from operating activities (A)*	33.00	62,007,361	57,536,960
Cash flows from Investing Activities			
Acquisition of Property, Plant and Equipment	30.00	(33,475,308)	(5,504,395)
Cash Payments for Capital Work-in-progress		(32,691,640)	(44,968,713)
Cash Payments for FDR		(12,397,969)	(272,163)
Net cash used in investing activities (B)		(78,564,917)	(50,745,271)
Cash flows from Financing Activities			
Short Term Loan received/(Repaid)		(359,594)	1,477,237
Cash payment for Financial Expenses		(366,291)	(418,260)
Cash payment towards lease liabilities		(1,671,373)	(1,623,120)
Cash Dividend Paid		(31,826)	(548,325)
Net cash used in financing activities (C)		(2,429,084)	(1,112,468)
Net increase/(decrease) of Cash and Cash Equivalents (A+B+C)		(18,986,640)	5,679,221
Cash and Cash Equivalents at the beginning of the period	10.00	58,662,709	36,412,280
Cash and Cash Equivalents at the end of the period	10.00	39,676,069	42,091,501
Net Operating Cash Flow Per Share (NOCFPS)	31.00	0.45	0.42
Number of Shares used to compute NOCFPS		136,500,000	136,500,000

*Refer to Note 33.00 for a reconciliation between net profit with cash flows from operating activities.



Chairman



Managing Director



Director



Chief Financial Officer



Company Secretary